Granty a projekty

Inhibitory tyrosinkinas jako nástroje k překonání lékové rezistence způsobené karbonyl-redukujícími enzymy

Anthracyclines have been the most widely used drugs for cancer treatment for many years. The increasing resistance of malignant cells to anthracyclines and their cardiotoxic side effects are reasons for the failure of chemotherapy. It is known, that some aldo-keto reductases (AKRs) and carbonyl reductases (CBRs) are enzymes responsible for reduction of anthracyclines to their less potent metabolites. Recent studies show that some TKi are able to sensitize tumor cells to anthracyclines. Our preliminary data with Brivanib, a TKi that is currently in Phase III clinical trials, indicate that Brivanib can act as a promising inhibitor of AKR1C3. It is therefore of great interest to test whether some other TKi, that are currently in (pre)clinical trials can act as reversal agents for anthracycline resistance mediated by carbonyl reducing enzymes. The aim of the project is to investigate a potential interaction of novel tyrosine kinase inhibitors (TKi) with carbonyl reducing enzymes.

Číslo: GAUK1006218

Období: 01.01.2018 - 31.12.2020

Poskytovatel: Univerzita Karlova - Grantová agentura UK

Hlavní řešitel: Büküm Neslihan, Ph.D. - Farmaceutická fakulta v Hradci Králové

Celkový objem financí: 840 000,00 Kč

Interní řešitelé

Spoluřešitel: PharmDr. Kamila Krtilová - Farmaceutická fakulta v Hradci Králové, FaF HK
Spoluřešitel: Mgr. Alžbeta Tomanová - Farmaceutická fakulta v Hradci Králové, FaF HK
Spoluřešitel: PharmDr. Lucie Havlíčková - Farmaceutická fakulta v Hradci Králové, FaF HK
Spoluřešitel: RNDr. Bc. Eva Novotná, Ph.D. - Univerzita Karlova,
Školitel: prof. Ing. Vladimír Wsól, Ph.D. - Univerzita Karlova,